The abstract is read at the publisher; the summary is JClub's.
Higher blood levels of MMP12 are linked to a lower risk of incident ischemic stroke, with Mendelian randomization supporting a direct protective effect.
- Why it matters: Preventive therapies for ischemic stroke have lagged because the molecular mechanisms and actionable protein targets remain incompletely defined.
- What they did: In ARIC and CHS participants without prevalent stroke at proteomic profiling (aptamer proteomics; n=4954), Cox models were meta-analyzed, then Mendelian randomization tested protein–stroke associations.
- The result: Mendelian randomization suggested MMP12 and CNTN1 may be causally related to ischemic stroke risk, and multivariable analyses indicated MMP12 has a direct protective effect while CNTN1 has a direct harmful effect.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.